Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Amylin Pharmaceuticals (NasdaqNM:AMLN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 14Earnings Announcement
July 27Conference call: SYMLIN(tm) FDA Advisory Committee Results
Location
9373 Towne Centre Drive
San Diego, CA 92121
Phone: (858) 552-2200
Fax: (858) 552-2212
Employees (last reported count): 151
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Divisions
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 44%
·Over the last 6 months:
 · one insider buy; 10.0K shares
·Institutional: 40% (71% of float)
(127 institutions)
·Net Inst. Buying: 10.6M shares (+28.36%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Amylin Pharmaceuticals, Inc. is engaged in the discovery, development and commercialization of potential drug candidates for the treatment of metabolic disorders. The Company is developing Symlin (pramlintide acetate) for the treatment of diabetes patients who use insulin. Symlin is a synthetic analog of the human hormone amylin that was invented by the Company's scientists. The Company has completed clinical testing of Symlin that it believes is sufficient to support United States Food and Drug administration approval to market Symlin. The Company submitted a New Drug Application for Symlin to the FDA in December 2000, and this application was filed for review by the FDA in January 2001. The Company anticipates submitting a Marketing Approval Application for Symlin to regulatory authorities in Europe in the second quarter of 2001. The Company's other drug candidates are AC2993, AC3056 and AC2993 LAR.
More from Market Guide: Expanded Business Description

Financial Summary
Amylin Pharmaceuticals, Inc. is engaged in the discovery and development of potential drug candidates for the treatment of metabolic discorders. For the six months ended 6/30/01, the company reported no revenues. Net loss increased 71% to $34.4 million. Results reflect the absence of any collaborative agreement revenues. Higher losses reflect an increase in development cost associated with the AC2993 LAR development program and an increase in employees.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Joseph Cook, Jr., 59
Chairman and CEO
$588K$190K
Daniel Bradbury, 39
Exec. VP
395K778K
Julia Brown, 54
Exec. VP
--  --  
Martin Brown, 54
Sr. VP, Operations
344K566K
Joann Data, M.D., Ph.D., 56
Sr. VP of Regulatory Affairs and Quality Assurance
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AMLNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 9-Jan-2001
$5.00 
Recent Price$7.22 
52-Week High
on 21-June-2001
$15.01 
Beta0.12 
Daily Volume (3-month avg)1.33M
Daily Volume (10-day avg)323.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-47.0%
52-Week Change
relative to S&P500
-28.9%
Share-Related Items
Market Capitalization$485.7M
Shares Outstanding67.3M
Float37.7M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.48 
Earnings (ttm)-$0.91 
Earnings (mrq)-$0.30 
SalesN/A 
Cash (mrq)$1.26 
Valuation Ratios
Price/Book (mrq)14.92 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$55.9M
Income available to common (ttm)-$58.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-61.15%
Return on Equity (ttm)-164.26%
Financial Strength
Current Ratio (mrq)9.80 
Debt/Equity (mrq)1.71 
Total Cash (mrq)$84.7M
Short Interest
As of 8-Aug-2001
Shares Short11.2M
Percent of Float29.7%
Shares Short
(Prior Month)
8.99M
Short Ratio6.57 
Daily Volume1.71M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.